Navigation Links
Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
Date:3/4/2008

AUSTIN, TX and TORONTO, March 4 /PRNewswire/ - Affinium Pharmaceuticals today announced that they have commenced the dosing of healthy subjects in a Phase I study of AFN-1252, one of its lead clinical candidates from its novel class of fatty acid biosyntheis inhibitors. The study of AFN-1252 will evaluate the safety, tolerability and pharmacokinetics of a single escalating oral dose. Affinium believes that AFN-1252 will provide patients and their doctors a potent, oral and IV treatment for susceptible and resistant staphylococcal infections both in and out of hospitals.

AFN-1252 is an investigational antibiotic, with a novel mechanism of action, and very high potency against all drug-resistant phenotpyes of staphylococci including hospital and community-acquired MRSA. Oral bioavailability has previously been demonstrated in a human microdosing study and excellent in vivo efficacy has been demonstrated in various animal models of infection.

"Affinium is very pleased to advance this novel class of antibiotics with great potential to address the serious unmet medical need for new oral and IV antibiotics capable of treating multi-drug resistant staphylococcal infections," said Dr. Barry Hafkin, Chief Medical Officer of Affinium Pharmaceuticals. "In preclinical studies, AFN-1252 was well tolerated at high multiples of the projected human dose in two species, suggesting a safety profile that would be very attractive to physicians practicing both in and out of hospital settings." Dr. Hafkin added that "the specific-spectrum of activity of AFN-1252 may provide further safety advantages by decreasing the risk of gut and cutaneous flora disruption."

About Affinium Pharmaceuticals

Affinium Pharmaceuticals is a specialty pharmaceutical company focused on the discovery, development and commercialization of novel anti-infective medicines. AFN-1252 utilizes a unique mechanism of action by directly inhibiting the function of the bacterial fatty acid synthesis (FAS) II pathway. Affinium's FASII antibacterial programs constitute a new antibiotic franchise with the potential for multiple products targeting the FASII pathway. These programs include a broad base of long-term intellectual property: issued and pending composition of matter patents on potent orally available small molecule inhibitors of a new class of antibiotics with a unique mechanism of action, targeting an underexploited pathway and are not subject to resistance selection pressures caused by the use of existing broad spectrum antibiotics.


'/>"/>
SOURCE Affinium Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
2. Renhuang Pharmaceuticals, Inc. Retains CCG Elite
3. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
4. Jazz Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 13, 2008
5. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
6. Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR
7. Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR
8. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
9. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
10. American Stock Exchange LLC to Delist Securities of Samaritan Pharmaceuticals, Inc.
11. Law Offices of Howard G. Smith Announces 25 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Threshold Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... The new ... medium and small physician practices, to better grasp and implement HIPAA’s privacy, security, ... guides practices on a well-defined, expert-created path to compliance. HIPAA Institute has positioned ...
(Date:5/2/2016)... ... May 03, 2016 , ... RNK ... sSOIP telemedicine stethoscope software that enables the stethoscope stream to go over the ... works with RNK’s flagship PCP-USB stethoscope. , Remote auscultation involves two software elements ...
(Date:5/2/2016)... Texas (PRWEB) , ... May 02, 2016 , ... ... 3, Issue 1 of Patient Experience Journal (PXJ), an international, open access, ... experience. With almost half the issue representing international (non-US) based authors, the third ...
(Date:5/2/2016)... Texas (PRWEB) , ... May 02, 2016 , ... The ... a time to honor the civilian nurses that care for its uniformed service members, ... signed a proclamation in 1974 designating May 6th through May 12th National Nurses Week. ...
(Date:5/2/2016)... ... May 02, 2016 , ... In honor of National Physical Fitness and ... people who share their fitness journey on social media. , The foot care ... award a $100 product voucher each week during May to one winner. , “Whether ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... April 29, 2016 Automation is ... laboratory due to the growing demands for productivity in ... contemporary automated systems are already adept of a wide ... tedious and manual labor. Instrumentation continues to evolve, and ... conceivable just a few years ago. Originally used mostly ...
(Date:4/28/2016)... 28, 2016 Research and Markets ... Surgery Products Market 2016-2020" report to their offering. ... The global plastic surgery products market is ... the period 2016-2020. , ,The growing adoption of laser ... growth of the market. Lasers are used to treat ...
(Date:4/28/2016)... , April 28, 2016  The blood testing ... million dollars, according to Kalorama Information and The Freedonia ... immunoassays and nucleic acid testing.  The healthcare research firm ... progress in developing blood collection stations and in improving ... in Kalorama Information,s report, Blood Testing Market ...
Breaking Medicine Technology: